← Back
Data updated: Mar 10, 2026
CHARTWELL MOLECULES
Immunology
CHARTWELL MOLECULES is a pharmaceutical company focused on Immunology.
1971
Since
16
Drugs
-
Trials
232
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
DILTIAZEM HYDROCHLORIDE 2026-02-23
Labeling
DILTIAZEM HYDROCHLORIDE 2026-02-23
Labeling
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-13
SULFAMETHOXAZOLE AND TRIMETHOPRIM 2026-02-10
Labeling
DILTIAZEM HYDROCHLORIDE 2026-01-24
Labeling
DILTIAZEM HYDROCHLORIDE 2026-01-24
Labeling
ACYCLOVIR 2026-01-22
Labeling
DILTIAZEM HYDROCHLORIDE 2026-01-18
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Immunology 100%
2 drugs
Pipeline Strength Pro
Loading...
Discontinued (11)
Company Info
- First Approval
- 1971-04-14
- Latest
- 2025-09-04
- Applications
- 21